6/3/2023 0 Comments AndexxaAnticoagulant-associated ICrH results in larger hematoma volumes, higher risk of expansion, and worse clinical outcomes compared with spontaneous ICrH. 1 A serious adverse consequence of these medications is acute major bleeding, the most serious being intracranial hemorrhage (ICrH). A 1-way sensitivity analysis found that for the incremental cost-effectiveness ratio to be <$150 000/QALY gained, Andexanet high or standard dosing would require a price reduction to <$24 000 Canadian (at current baseline efficacy).įactor Xa inhibitors (apixaban, edoxaban, and rivaroxaban) are preferred over warfarin for prevention of ischemic stroke in patients with nonvalvular atrial fibrillation and the treatment/prevention of venous thromboembolism. The probabilistic sensitivity analyses demonstrated that Andexanet (at its current cost) was cost-effective in 19% of simulations using a willingness-to-pay threshold of $50 000/QALY and 33% of simulations at $150 000/QALY. The strategy of Andexanet had an incremental cost-effectiveness ratio was $219 652 per QALY gained compared with the comparator of PCC. ![]() The average discounted lifetime costs were $237 177 Canadian dollars for Andexanet and $177 871 Canadian dollars for PCC. PCC had a discounted life expectancy of 2.09 years and a discounted QALY of 1.28. Andexanet had the highest discounted life expectancy of 2.53 years and a discounted QALY of 1.55. Customer Service and Ordering InformationĪn overall reduction in fatal ICrH and increase in thromboembolic events was associated with Andexanet compared with PCC. ![]()
0 Comments
Leave a Reply. |